Literature DB >> 4722571

L-dopa level in plasma, primary condition for the kinetic effect.

W Birkmayer, W Danielcyk, E Neumayer, P Riederer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4722571     DOI： 10.1007/BF01244666

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


× No keyword cloud information.
  15 in total

1.  THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1964-09       Impact factor: 4.030

2.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

3.  [Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)].

Authors:  W Birkmayer; M Mentasti
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1967-08-08

4.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

Review 5.  [Biochemical bases for the treatment of Parkinson's syndrome with L-dopa].

Authors:  A Pletscher; G Bartholini; K F Gey; A Jenni
Journal:  Schweiz Med Wochenschr       Date:  1970-05-09

6.  [Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].

Authors:  F Geissbühler; J Constantinidis; J J Eisenring; M Krassoievitch; G Yanniotis; R Tissot
Journal:  Clin Chim Acta       Date:  1971-06       Impact factor: 3.786

7.  [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].

Authors:  W Danielczyk; J J Korten
Journal:  Med Monatsschr       Date:  1971-10

8.  L-dopa treatment failure: explanation and correction.

Authors:  L Rivera-Calimlim; C A Dujovne; J P Morgan; L Lasagna; J R Bianchine
Journal:  Br Med J       Date:  1970-10-10

9.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

Authors:  M D Muenter; G M Tyce
Journal:  Mayo Clin Proc       Date:  1971-04       Impact factor: 7.616

10.  [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].

Authors:  W BIRKMAYER; O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1961-11-10       Impact factor: 1.704
View more
  6 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.

Authors:  R J Hardie; S L Malcolm; A J Lees; G M Stern; J G Allen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

4.  Intestinal absorption of levodopa in man.

Authors:  U Gundert-Remy; R Hildebrandt; A Stiehl; E Weber; G Zürcher; M Da Prada
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  The Human Experience with Intravenous Levodopa.

Authors:  Shan H Siddiqi; Natalia K Abraham; Christopher L Geiger; Morvarid Karimi; Joel S Perlmutter; Kevin J Black
Journal:  Front Pharmacol       Date:  2016-01-06       Impact factor: 5.810

Review 6.  Antiparkinson prodrugs.

Authors:  Antonio Di Stefano; Piera Sozio; Laura Serafina Cerasa
Journal:  Molecules       Date:  2008-01-16       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.